Nektar Therapeutics Q4 2024 Adj. EPS $(0.15) Beats $(0.17) Estimate, Sales $29.200M Miss $29.860M Estimate

-5.46% Post

Nektar Therapeutics

NKTR

0.76

0.77

-5.46%

+2.01% Post

Nektar Therapeutics (NASDAQ: NKTR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.17) by 11.76 percent. The company reported quarterly sales of $29.200 million which missed the analyst consensus estimate of $29.860 million by 2.21 percent. This is a 22.25 percent increase over sales of $23.885 million the same period last year.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.